Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Pieris Pharmaceuticals, Inc.. (2/19/18). "Press Release: Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference". Boston, MA.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 RBC Capital Markets, LLC
Products Product RBC Capital Markets Global Healthcare Conference 2018 New York
  Product 2 Anticalin® scaffold technology
Index term Index term Pieris–RBC Capital Markets: investor conference, 201802 supply service Pieris presents at RBC Capital Markets Global Healthcare Conference
Persons Person Reine, Allan (Pieris 201708– CFO before Lombard Odier Asset Management + serveral Funds + CIBC World Markets)
  Person 2 Schweitzer, Gretchen (Trophic Comunications 201801 before MacDougall European Office)
     


Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of the management team will present at the RBC Healthcare Conference on Thursday, February 22, 3:35 pm EST at The New York Palace Hotel, New York City. A webcast of the Company's presentation will be available at this link.


About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.


Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; the timing and progress of our studies, including the timing of enrollment and dosing of PRS-343 patients and PRS-060 healthy subjects; the enrollment of patients in the PRS-080 multi-dose trial and dosing healthy subjects; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Company's Quarterly Reports on Form 10-Q.


Company Contact:

Allan Reine
SVP & Chief Financial Officer
+1-857-444-4276
reine@pieris.com

Investor Relations Contact:
The Trout Group
Thomas Hoffmann
+1-646-378-2931
thoffmann@troutgroup.com

Media Inquiries:
Trophic Communications
Gretchen Schweitzer
+49 89 238 87730
schweitzer@trophic.eu

   
Record changed: 2018-03-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top